Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine... | Completed
Safety and Efficacy Study of 2 Panc... | Completed
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.

Trial Source

Location not identified by Google services

Location data is sourced from multiple external providers and UKCTG is not responsible for and cannot guarantee the accuracy of data.

Medical Conditions
  • Exocrine Pancreatic Insufficiency: Cystic Fibrosis
Unfortunately contact details are not available for this trial.
Primary Contact Details
Completed
Recruitment Status
NCT01641393
Primary Trial ID Number

We need your help to advance medical research

You can help accelerate the discovery of cures of medical conditions by signing up and creating a profile. By doing so you can register your interest in clinical trials and researchers will be able to get in touch about trials that are suitable for you.

This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Summary
The purpose of the study is to further evaluate the safety and efficacy of EUR-1008 as compared to Kreon® in the treatment of exocrine pancreatic insufficiency associated with Cystic Fibrosis in subjects 12 years of age and older.
Research Details
    Sorry, this information is not available
Phase
Phase 3
Study Design
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Study Type
Interventional
Intervention
Drug : EUR-1008 25,000 Units, Drug : Kreon 25,000 Units

Study Arm Groups : EUR-1008 then Kreon, Kreon then EUR-1008, EUR-1008 then Kreon, Kreon then EUR-1008

Intervention Type
See Interventions above
Primary Outcome Measures
    Coefficient of Fat Absorption over 72 hours (CFA-72h); 72 hours
Secondary Outcome Measures
    Body weight; 58 days.; Coefficient of nitrogen absorption; 72 hours; Control of signs and symptoms of EPI; 2- 14 day periods; Impact on overall health, daily life, perceived well-being, and symptoms; 58 days; Total cholesterol, calculated LDL-C, HDL-C; 58 days; Treatment Emergent Adverse Events; 78 days; Standard safety laboratory tests; 58 days; Vital signs; 78 days; Fat-soluble vitamins A, D, and E; 58 days
Publication(s)
Sorry, this information is not available
Result Reports
Check availability of results on the Clinicaltrials.gov website
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Gender
Both
Age Range
12 Years - N/A
Who Can Participate
Patients
Number of Participants
Sorry, this information is not available
Participant Inclusion Criteria
    Inclusion Criteria:

    1. Definitive diagnosis of CF based on the following:

    - One clinical feature consistent with CF and

    - Either a genotype with 2 identifiable mutations known to cause CF or a sweat chloride concentration >60 mEq/L by pilocarpine iontophoresis

    2. Pancreatic insufficiency documented by a monoclonal faecal elastase (FE) 100 μg/g stool at screening (test results within the previous 12 months are acceptable)

    3. Currently receiving pancreatic enzyme replacement therapy

    4. Adequate nutritional status based on the following: body mass index (BMI) >19 kg/m2 in adult subjects or a BMI percentile 10th percentile for age in adolescent (12 to 17 years age group) subjects

    5. Are clinically stable with no evidence of concomitant illness or acute upper or lower respiratory tract infection that requires antibiotics during the 7-day interval prior to screening and preceding entry into this clinical study

    Exclusion Criteria:

    1. Age <12 years

    2. Known contraindication, hypersensitivity, or intolerance to pork or other porcine PEPs

    3. Current uncontrolled diabetes mellitus

    4. History of solid organ transplantation

    5. History of surgery affecting the bowel function and weight gain
Participant Exclusion Criteria
This is in the inclusion criteria above
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Trial Location(s)
Heart & Chest Hospital
Liverpool
Sheffield
Trial Contact(s)
Primary Trial Contact
Sorry, this information is not available
Other Trial Contacts
Sorry, this information is not available
Countries Recruiting
Belgium, Bulgaria, France, Germany, Italy, Poland, United Kingdom
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Scientific Title
A Randomised, Double-Blind, Active-Controlled, Two-Treatment, Crossover, Multinational, Multicentre Study to Compare Two Pancreatic Enzyme Products in the Treatment of Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis
EudraCT Number
Not available for this trial
Funder(s)
    Sorry, this information is not available
Other Study ID Numbers
PR-005
Sponsor(s)
Forest Laboratories
Key Dates

Recruitment Start Date

Jun 2012

Recruitment End Date

Feb 2014

Trial Start Date
Date Not Available
Trial End Date
Date Not Available
Date added to source

10 Jul 2012

Date updated in source

13 Mar 2014